Items Tagged ‘T790M mutation’

November 19th, 2015

Novel Precision Medicine Tagrisso Approved for Treatment of Lung Cancer


The United States Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the treatment of lung cancer with the epidermal growth factor receptor (EGFR) T790M mutation. The indication specifies that patients must have non-small cell lung cancer (NSCLC) that has progressed despite treatment with other approved agents that block the EGFR pathway. The diagnostic […]

View full entry

Tags: Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, osimertinib, T790M mutation, tagrisso